Beam Therapeutics Inc Overview
Industry: Biotechnology
Sector: Healthcare
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 and BEAM-102 for the treatment of sickle cell disease beta thalassemia; BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease; and the Institute of Molecular and Clinical Ophthalmology Basel for treatment of impaired vision and blindness. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts. Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 and BEAM-102 for the treatment of sickle cell disease beta thalassemia; BEAM-201, an allogeneic chimeric Read MoreMavefund brings filings, fundamentals, valuation, price history and news for Beam Therapeutics Inc into one research view. The sections below show what strengthens or weakens the research case.
Score
Reported Results
What the company reported, with filing details kept small.
Quarterly result summary
Revenue was $31.7M (+325% YoY). Net loss was -$94.3M. Cash was $1.2B.
Revenue
$31.7M
+325% YoY
Net loss
-$94.3M
reported
Cash
$1.2B
reported
What changed
- Revenue +325% YoY to $31.7M.
Guidance / outlook
the company anticipates enrolling approximately 50 additional patients with AATD-associated lung disease, with or without liver disease, in an expansion of the ongoing open-label Phase 1/2 trial.
Earnings release
Open filing
Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.
Other recent earnings materials
SEC filing
8-K
May 07, 2026
SEC filing
10-Q
May 07, 2026
SEC filing
10-K
Feb 24, 2026
Earnings release
Earnings release
Feb 24, 2026
Earnings material
Earnings release
Jan 12, 2026
SEC filing
8-K
Jan 12, 2026
SEC filing
10-Q
Nov 04, 2025
SEC filing
8-K
Nov 04, 2025
Earnings material
Earnings release
Nov 04, 2025
SEC filing
10-Q
Aug 05, 2025
Prediction-grade evidence
Recent News
Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.
Beam Therapeutics to present BEAM-302 data at September conference By Investing.com
Headline from Investing.com Nigeria: Beam Therapeutics to present BEAM-302 data at September conference By Investing.com.
Beam Therapeutics to Present Updated Data from Phase 1/2
Headline from GlobeNewswire: Beam Therapeutics to Present Updated Data from Phase 1/2.
Beam Healthcare and Simvuly Expand Access to Board-Certified Specialists for Every U.S. Clinician
Headline from Yahoo Finance: Beam Healthcare and Simvuly Expand Access to Board-Certified Specialists for Every U.S. Clinician.
Beam Global receives battery orders exceeding $500,000
Headline from Investing.com: Beam Global receives battery orders exceeding $500,000.
Beam Global Receives Drone and Autonomous Robotics Battery Orders Exceeding $0.5 Million In a Single Week
Headline from GlobeNewswire: Beam Global Receives Drone and Autonomous Robotics Battery Orders Exceeding $0.5 Million In a Single Week.
Innovative CBD-Coated Bedding Clinically Proven to Improve Sleep Quality: Song Beam Bedding and China Medical University's Joint Study Published in International Journal Healthcare
Headline from Yahoo Finance: Innovative CBD-Coated Bedding Clinically Proven to Improve Sleep Quality: Song Beam Bedding and China Medical University's Joint Study Published in International Journal Healthcare.
Earnings Per Share
Score 3.00/5
Beam Therapeutics Inc boasts a high score, as its Earnings Per Share (EPS) has demonstrated consistent growth over the past six years. Notable counterparts in the sector with high scores includes
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
In
Biotechnology industry
, Halozyme Therapeutics Inc
, Corcept Therapeutics Incorporated
, Exelixis Inc
are companies with high ratings.
Return on Equity
Score 1.46/5
Beam Therapeutics Inc exhibits a lower score in the Return on Equity (ROE) section, falling below the sector median value and indicating a comparatively weaker performance in this metric. The top companies in the same sector include
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
0%
10%
20%
30%
40%
ROE
Company —
Sector Median —
0%
10%
20%
30%
40%
ROE
Company —
Sector Median —
0%
10%
20%
30%
40%
ROE
Company —
Sector Median —
0%
10%
20%
30%
40%
ROE
Company —
Sector Median —
Metric chart temporarily unavailable.
Net Margin
Score 0.81/5
Beam Therapeutics Inc
olds a low score as its net margin consistently trails below the sector median value and doesn't exhibit continuous growth over the last six years; notable companies in the sector with commendable scores include
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
0%
10%
20%
30%
40%
Net Margin
Company —
Sector Median —
0%
10%
20%
30%
40%
Net Margin
Company —
Sector Median —
0%
10%
20%
30%
40%
Net Margin
Company —
Sector Median —
0%
10%
20%
30%
40%
Net Margin
Company —
Sector Median —
Metric chart temporarily unavailable.
Leverage
Score 2.39/5
Beam Therapeutics Inc
registers a lower score in the category as a result of its elevated leverage ratio over the past six years compared to the sector median value. Conversely, other companies in the same sector, including
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
have achieved high scores.
0
1
2
3
4
Leverage
Company —
Sector Median —
0
1
2
3
4
Leverage
Company —
Sector Median —
0
1
2
3
4
Leverage
Company —
Sector Median —
0
1
2
3
4
Leverage
Company —
Sector Median —
Metric chart temporarily unavailable.
Financial Statements
Company-reported SEC EDGAR facts organized into the three core statements.
Verified SEC statements load when this section enters view.
Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.
Financial Ratio
Yearly
Quarterly
Financial
Profitability
Growth
Cash Flow
Financial Health
Efficiency Ratios